UK tech firm announces discovery partnership with Boehringer

Bactevo, a UK tech firm with a focus on drug discovery, has announced a collaboration with privately-held German pharma major Boehringer Ingelheim.

The company has developed a novel system of drug discovery that it has named TIME (totally integrated medicines engine). The technology combines microfluidics, nanofabrication and artificial intelligence to disrupt current methods of creating new medicines.

Boehringer has not disclosed the programs with which it intends to use Bactevo's technologies, nor has it been announced what the value of the deal is. We do know, however, that Bactevo will receieve some upfront payments and funding for additional research, with future payments for milestones met.